JP2011225577A5 - - Google Patents

Download PDF

Info

Publication number
JP2011225577A5
JP2011225577A5 JP2011121017A JP2011121017A JP2011225577A5 JP 2011225577 A5 JP2011225577 A5 JP 2011225577A5 JP 2011121017 A JP2011121017 A JP 2011121017A JP 2011121017 A JP2011121017 A JP 2011121017A JP 2011225577 A5 JP2011225577 A5 JP 2011225577A5
Authority
JP
Japan
Prior art keywords
agent
remyelinating
treat
preparing
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011121017A
Other languages
English (en)
Other versions
JP2011225577A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011225577A publication Critical patent/JP2011225577A/ja
Publication of JP2011225577A5 publication Critical patent/JP2011225577A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 脱髄疾患を治療するために哺乳類の神経細胞の再有髄化を促進する量の再有髄化剤で薬剤を使用し、調製することを特徴とする再有髄化剤の使用方法。
JP2011121017A 2003-01-24 2011-05-30 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療 Pending JP2011225577A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44217103P 2003-01-24 2003-01-24
US60/442,171 2003-01-24
US50031603P 2003-09-05 2003-09-05
US60/500,316 2003-09-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006503001A Division JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013210543A Division JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Publications (2)

Publication Number Publication Date
JP2011225577A JP2011225577A (ja) 2011-11-10
JP2011225577A5 true JP2011225577A5 (ja) 2012-08-30

Family

ID=32829779

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006502997A Pending JP2006516624A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2006503001A Pending JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2011121017A Pending JP2011225577A (ja) 2003-01-24 2011-05-30 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2013210543A Pending JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006502997A Pending JP2006516624A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2006503001A Pending JP2007521249A (ja) 2003-01-24 2004-01-26 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013210543A Pending JP2014040458A (ja) 2003-01-24 2013-10-07 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Country Status (16)

Country Link
US (2) US20050069541A1 (ja)
EP (4) EP3527228A1 (ja)
JP (4) JP2006516624A (ja)
KR (2) KR101260497B1 (ja)
AU (5) AU2004207535A1 (ja)
CA (2) CA2514117A1 (ja)
CO (1) CO5670359A2 (ja)
IL (1) IL169770A (ja)
MX (2) MXPA05007843A (ja)
NO (1) NO20053920L (ja)
PE (1) PE20040942A1 (ja)
RU (1) RU2412721C2 (ja)
SK (1) SK50642005A3 (ja)
TW (2) TW201311238A (ja)
UY (1) UY28170A1 (ja)
WO (2) WO2004066931A2 (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
TWI346558B (en) 2002-02-25 2011-08-11 Elan Pharm Inc Pharmaceutical composition for chronic treatment of inflammation and use thereof
KR101260497B1 (ko) 2003-01-24 2013-09-12 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물
US7595318B2 (en) 2004-01-23 2009-09-29 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
TWI418346B (zh) 2004-07-08 2013-12-11 Elan Pharm Inc 包括聚合物部分之多價ｖｌａ-４拮抗劑
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
JP2008522971A (ja) * 2004-12-03 2008-07-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症の発症の遅延または予防
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
US8030328B2 (en) 2005-05-20 2011-10-04 Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives
WO2007050583A2 (en) * 2005-10-26 2007-05-03 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
US20070106035A1 (en) * 2005-10-26 2007-05-10 Medivas, Llc Aromatic di-acid-containing poly (ester amide) polymers and methods of use
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US9008378B2 (en) 2006-12-20 2015-04-14 The Board Of Trustees Of The Leland Stanford Junior University Arrangement and imaging of biological samples
WO2009029936A1 (en) * 2007-08-31 2009-03-05 Case Western Reserve University In vivo imaging of myelin
AU2009298888A1 (en) * 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
AU2010236257A1 (en) * 2009-04-17 2011-11-03 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
US20120258093A1 (en) * 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP3466977B1 (en) 2010-04-16 2022-01-05 Biogen MA Inc. Anti-vla-4 antibodies
US20130190299A1 (en) * 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
EP2632492B1 (en) 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
CA2818548A1 (en) * 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
WO2013025897A1 (en) 2011-08-16 2013-02-21 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
PT3590960T (pt) 2012-02-29 2023-04-18 Takeda Pharmaceuticals Co Remielinização estimulada por igg de nervos periféricos
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
WO2014058875A2 (en) * 2012-10-09 2014-04-17 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2015048819A1 (en) * 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
CA2938946A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
KR20170052526A (ko) * 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
KR102364840B1 (ko) 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
EP3229797A4 (en) * 2014-12-12 2018-08-15 Commonwealth Scientific and Industrial Research Organisation Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN106316982B (zh) * 2015-06-30 2020-08-14 中国人民解放军军事医学科学院毒物药物研究所 噻嗪酰胺衍生物及其用途
US10947311B2 (en) * 2015-11-20 2021-03-16 The Board Of Trustees Of The Leland Stanford Junior University VCAM-1 mediated methods and compositions for treating aging-associated impairments
CN112119089A (zh) * 2018-05-23 2020-12-22 瑞士杰特贝林生物制品有限公司 Cidp的治疗
KR20210027352A (ko) 2018-06-04 2021-03-10 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2122732C (en) 1991-11-25 2008-04-08 Marc D. Whitlow Multivalent antigen-binding proteins
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
WO1996010585A1 (en) 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6306384B1 (en) 1996-10-01 2001-10-23 E-L Management Corp. Skin battery cosmetic composition
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1017382B1 (en) * 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) * 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811594A (pt) * 1997-07-31 2000-09-05 Elan Pharm Inc Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
CA2291473A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
CN1265674A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
US6362341B1 (en) * 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
AR013384A1 (es) * 1997-07-31 2000-12-27 Athena Neurosciences Inc Compuestos del tipo de fenilalanina substituidos que inhiben la adhesion de leucocitos intermediada por vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US7030114B1 (en) * 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) * 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
WO2000044408A2 (en) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
WO2001054690A1 (en) 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
AU6197800A (en) * 2000-05-10 2001-11-20 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
US6653313B2 (en) * 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
WO2002033377A2 (en) * 2000-09-20 2002-04-25 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
TWI346558B (en) * 2002-02-25 2011-08-11 Elan Pharm Inc Pharmaceutical composition for chronic treatment of inflammation and use thereof
KR101260497B1 (ko) 2003-01-24 2013-09-12 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료 및 조성물
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor

Similar Documents

Publication Publication Date Title
JP2011225577A5 (ja)
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
SG11201400466TA (en) Eukaryotic organisms and methods for producing 1,3-butanediol
ZA201404077B (en) Neutralizing antibodies to hiv -1 and their use
MX2014002087A (es) Formulaciones piretroides.
ZA201305844B (en) Catalyst which can be used in hydrotreatment and which inludes group vii metals and group vib metals,and preparation thereof using citric acid c1-c4 dialkyl succinate
JP2012143233A5 (ja)
ZA201401562B (en) Agrochemical composition uses and preparation process thereof, as well as method to ensure high crop yield
GB201220065D0 (en) Matrix for generating and cultivating uniform cell aggregations, method for producing a matrix and use of a matrix
EP2712928A4 (en) PROCESS FOR THE PRODUCTION OF NATURAL CARBOHYDRATE BY FERMENTATION AND ITS APPLICATIONS
HUE049168T2 (hu) L-aminosav elõállítására képes mikroorganizmus és eljárás L-aminosav elõállítására annak alkalmazásával
EP2701700A4 (en) PHARMACEUTICAL THERAPY FOR INHIBITING CHEMOTHERAPY-INDUCED SIDE EFFECTS AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHOD AND KITS
EP2851119A4 (en) CATALYST FOR USE IN THE PREPARATION OF METACRYLIC ACID, METHOD FOR THE PRODUCTION OF THE CATALYST AND METHACRYLIC ACID PROCESS FOR THE PREPARATION OF THIS CATALYST
IL228951A0 (en) Methods and preparations for modulating gene expression by using components that are assembled independently in cells and produce rnai activity
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
IL232642A0 (en) A method for characterizing circulating cells and its use in diagnosis
HK1210722A1 (en) Method for producing extended-release potassium citrate wax matrix tablet
HUE057439T2 (hu) Terápiás vakcina 1-es típusú cukorbetegség kezelésére gyermekekben, sejtválogató alkalmazása és eljárás TREG sejtek sokszorosítására 1-es típusú cukorbetegség kezelésére szolgáló terápiás vakcina elõállítására
EP2740738A4 (en) PLATINUM COMPOUNDS FOR TREATING CELLULAR PROLIFERATIVE DISEASES, PREPARATION METHODS AND USES THEREOF
LU91877B1 (en) Method to predict the presence of itaconic Acid, IRG1 and/or protein IRG1 in a subject and pharmaceutical composition for performing gene therapy
EP2699672A4 (en) METHOD FOR PRODUCING VIRUSES IN CULTURED CELLS
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
EP2730586A4 (en) PROTEIN-PEPTIDE COMPLEX HAVING SPECIFIC ACTION ON DERMAL TISSUES, PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP2825040A4 (en) PROCESS FOR PREPARING BENZAZOQUOOLIUM (BQS) SALTS, USE OF THE COMPOSITION AS CELLULAR MARKERS AND USE OF THE BIOLOGICAL ACTIVITY OF THIS COMPOSITION
PL393021A1 (pl) Nowy szczep Trichoderma o podwyższonej aktywności biologicznej, zwłaszcza do stosowania w rolnictwie jako biofungicyd oraz sposób wytwarzania tego szczepu